



April 2018  
NASDAQ: **ORGS**

## Forward Looking Statements

---

This Presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking reflect management's current expectations, as of the date of this Presentation, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this Presentation are forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to differ materially from recent results or from those anticipated in these forward-looking statements include the Risk Factors described in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 28, 2017 and in our subsequent periodic reports with the SEC. you are cautioned not to place undue reliance on the forward-looking-statements, which speak only as of the date of this Presentation. we do not intend, and disclaim any obligation, to revise or update any forward-looking information contained in this Presentation or with respect to the matters described herein.

# About Orgenesis

## Fully-Integrated Cell Therapy Company; Leading the Revolution in Regenerative Medicine

- ✓ Direct benefits of operating global CDMO businesses while developing proprietary platform fuel investments for technology extension at optimized manufacturing costs



### Manufacturing

### Technology platform



#### Leading Global CDMO

Orgenesis is a premier service provider in the regenerative medicine industry. Orgenesis provides **contract development and manufacturing (CDMO)** services for many of the world's leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy.

Financial stability



Secured business

Secured manufacturing expertise & capacity



Recurring manufacturing revenue stream

Pipeline extension opportunities



Opportunity based consumables (e.g.reagent)

#### Transdifferentiation Platform


**Lead Indication: Insulin Dependent Diabetes.** Through our subsidiary Orgenesis Ltd., Orgenesis has developed a unique, proprietary technology platform that transforms the patient's own liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell, designed to provide long-term insulin independence.

# Proprietary Transdifferentiation Platform

## Development Pipeline Strategy

A unique, proprietary and patented platform technology whereby an adult cell is converted into another type of cell with distinct phenotype and function

*(Does not use stem cells, but rather offer a much more targeted approach using fully mature, adult cells)*




- Reduces the risk of cell mutation and allows for the testing of cells ex vivo before insertion
- Adult cells do not propagate inside the patient, eliminating the risk of malignancy
- Utilizes the patient's own autologous cells
  - Eliminates the risk of an immune response or rejection
  - No pouch or encapsulation device is required to isolate the cells from the patient's immune system.

### Potential across hundreds of indications and new cell sources

- Oncology
- Cardiovascular
- Musculoskeletal
- Dermatology
- Immunology & Inflammation
- Gastroenterology
- Hematology

## 3D clusters generation

Small scale generation of uniform 3D clusters for QC purposes



Scalable platform to allow future production of 3D IPCs



## Bioprinting Consortium – goals from our point

---

- Transfer knowledge to push forward the development of 3D bio-printing
- To find local partners for co-development projects
- To learn more about current possibilities and limitations in this field
- To initiate a “thinking group” to overcome current limitations



---

**Thank you.**

[www.orgenesis.com](http://www.orgenesis.com)